Acute Lymphoblastic Leukemia
Conditions
Brief summary
A randomised trial for children with acute lymphoblastic leukemia, using the detection of minimal residual disease to define risk groups, aiming to answer the questions: 1. Can treatment be reduced without compromising efficacy in a MRD-defined low risk group? 2. Does further post-remission intensification improve outcome for a MRD-defined high risk group? 3. Measure the Quality of Life impact of the different treatment arms on the children and their families.
Detailed description
Randomisations Patients will be assigned to MRD risk groups based on day 29 and post consolidation MRD results and randomised as follows: 1. MRD Low Risk Group (MRD negative at day 29 and week 11 or positive \<1 x 10-4 at day 28 and negative at week 11) will continue on previously assigned Regimens (A or B) but randomised between two delayed intensifications and one delayed intensification. 2. MRD High Risk Group (MRD positive \> 1 x 10-4 at day 29) randomised between previously assigned Regimen (A or B) and Regimen C. 3. MRD Indeterminate Group (No MRD result or MRD positive \<1 x 10-4 at day 29 and at week 11) will continue on previously assigned Regimen (A or B) and received two delayed intensifications
Interventions
OTHERReduced intensification
Deletion of one 7 week treatment block containing dexamethasone, vincristine, doxorubicin, Peg-asparaginase, intrathecal methotrexate, cyclophosphamide, cytarabine.
DRUGStandard childhood UK ALL protocol
No additional treatment to standard protocol.
DRUGIntensified treatment including Capizzi maintenance
Augmented consolidation: vincristine, Peg-asparaginase. Capizzi maintenance: iv methotrexate and peg-asparaginase
Sponsors
Medical Research Council
University of Oxford
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
Children aged 1 - 18 years with ALL except the following:
Exclusion criteria
1. Infants less than a year old should be entered onto the Interfant ALL study. 2. Children with B-ALL (Burkitt-like, t(8;14), L3 morphology, SMIg positive). Patients with this disease will be eligible for the current UKCCSG B cell NHL/ALL trial. 3. Children with Philadelphia-positive ALL (t(9;22) or BCR/ABL positive) will start induction therapy on this protocol but transfer to the European Intergroup Protocol as soon as their Philadelphia status is known. Initially, eligible patients will be stratified into three risk groups based on the following criteria: 1. Standard risk: all children \>1\<10 years with a highest white cell count before starting treatment of \<50x109/l, and who do not have BCR-ABL, hypodiploidy (≥44 chromosomes), or an MLL gene rearrangement. 2. Intermediate risk: all children ≥10 years old, or with a diagnostic WBC ≥50x109/l (or both) and who do not have BCR-ABL, hypodiploidy (≥44 chromosomes), or an MLL gene rearrangement. 3. High Risk: all children, irrespective of initial risk category, who have a slow early response (SER) as defined below - see section 6 - together with those who have BCR-ABL (induction only), hypodiploidy (≥44 chromosomes), or an MLL gene rearrangement. These patients will not be eligible for MRD randomisation. Patients will then start treatment according to their risk group as follows: 1. Standard risk, (around 60-65% of the total): regimen A - three-drug induction. 2. Intermediate risk, (around 20- 30% of the total): regimen B - four-drug induction. 3. High risk (around 10-12% of the total): These patients will not be eligible for MRD randomisation. They will be allocated regimen C - four drug induction, augmented BFM consolidation, Capizzi interim maintenance, and two further BFM-style intensification periods of extended duration. Inclusion criteria for entry into the randomisations: 1. Standard or Intermediate Risk as defined above. 2. Morphological Complete Remission (BM1 Marrow) at Day 29 of Induction. 3. Availability of MRD results at Day 28 and after consolidation therapy. 4. Informed consent obtained. 5. Induction given as protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event free survival | 5 years |
Secondary
| Measure | Time frame |
|---|---|
| Survival | 5 years |
| Quality of life | 3 years |
Countries
United Kingdom
Contacts
Primary ContactSusan Richards, D Phil
Outcome results
None listed